The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature by Meert, A-P et al.
Review
The role of HER-2/neu expression on the survival of patients with
lung cancer: a systematic review of the literature










1Fonds National de la Recherche Scientifique, Bruxelles, Belgium;
2De ´partement de Me ´decine Interne et Laboratoire d’Investigation Clinique et
d’Oncologie Expe ´rimentale HJ Tagnon, Institut Jules Bordet, 1, rue He ´ger Bordet, 1000-Bruxelles, Belgium;
3Data Centre, Institut Jules Bordet, Bruxelles,
Belgiuml;
4Service d’Anatomo-Pathologie, Institut Jules Bordet, Bruxelles, Belgium;
5Service de Pneumologie et d’Oncologie Thoracique, CHU Calmette,
Lille, France
C-erbB-2 prognostic value for survival in patients with lung cancer remains controversial. We performed a systematic review of the
literature to clarify its impact. Studies were identified by an electronic search in order to aggregate the survival results, after a
methodological assessment using the scale of the European Lung Cancer Working Party. To be eligible, a study had to deal with c-
erbB-2 assessment in lung cancer patients and to analyse survival according to c-erbB-2 expression. In total, 30 studies were eligible:
24 studies dealt with non-small-cell lung carcinoma (NSCLC), five with adenocarcinoma and one study dealt with small-cell
carcinoma. In all, 31% of the patients were positive for c-erbB-2. According to c-erbB-2 expression, 13 studies were ‘negative’
(significant detrimental effect on survival), one ‘positive’ (significant survival improvement) and 16 not significant. Significant studies
had a better subscore relative to analysis and results report than nonsignificant studies. In total, 86% of the significant studies and only
56% of the nonsignificant studies were evaluable for the meta-analysis. This suggests a possible bias in our aggregated results. For
NSCLC, the hazard ratio was 1.55 (95% CI: 1.29–1.86) in favour of tumours that do not express c-erbB-2. In conclusion, the
overexpression of c-erbB-2 might be a factor of poor prognosis for survival in NSCLC, but there is a potential bias in favour of the
significant studies with an overestimation risk of the magnitude of the true effect of c-erbB-2 overexpression.
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Lung carcinoma is the most common malignant neoplasm in the
developed world and represents the leading cause of cancer death
in Europe and North America. Surgical resection remains the
standard of care for patients with early-stage disease. Unfortu-
nately, 70% of all patients have inoperable disease and despite
improvements in the detection and treatment of lung cancer, less
than 15% are long-term survivors. This poor prognosis can,
however, be modulated by characteristics related to the patient or
the tumour. Some independent clinical and biological predictors
have been identified for predicting survival (Kanters et al, 1995;
Paesmans and Sculier, 1998): age, performance status, disease
stage, serum lactate dehydrogenase level, white blood cell and
neutrophil counts.
Currently, increased attention has been focused on new
biological parameters: biological substaging using molecular
markers in a risk stratification strategy has been proposed
(Pastorino et al, 1997; D’Amico et al, 1999), although their role
as a prognostic factor remains unclear. In particular, a number of
studies have been performed to assess the prognostic role of
tumour-suppressor genes and proto-oncogenes. Among the proto-
oncogenes, the epidermal growth factor (EGF) family plays an
important role in local tumour growth. This phenomenon requires
growth-regulatory proteins such as epidermal growth factor
receptor (EGF-R) or proto-oncogene erb-B2. The HER-2/neu
dominant gene is localised in normal human cells as a singular
copy on the long arm (q21) of chromosome 17. This gene, first
identified in a chemically induced rat neuroblastoma (Schechter
et al, 1984), codes for a 185-kDa receptor-type tyrosine protein
kinases (p185 neu or c-erbB-2) similar to EGF-R. This 1255 amino-
acid transmembrane glycoprotein is composed of three domains:
an extracellular factor-binding domain, a transmembrane domain
and an intracellular domain with tyrosine kinase activity. When an
EGF-like ligand (there is no known specific ligand for HER-2)
binds to a receptor of the EGF-R family (HER-1, 3 or 4), there is a
heterodimerisation of this receptor with HER-2. HER-2 is
necessary for the regulation of normal cell growth and differentia-
tion, and can be associated with multiple signal transduction
pathways (Hung and Lau, 1999). However, amplification of the
HER-2 gene leads to overexpression of the receptor, which is
linked to the formation of more HER-2 heterodimers and could
be implicated in the development of many types of tumours.
HER-2/neu is expressed in a wide variety of human epi-
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carcinomas, suggesting that its overexpression could play a critical
role in the development and progression of human cancers. The c-
erbB-2 protein product, p185, is expressed in 20–30% of non-
small-cell lung cancers (NSCLC) and particularly in adenocarci-
noma (Tateishi et al, 1991; Kern et al, 1994). Numerous studies
have suggested that HER-2 expression is associated with advanced
or metastatic disease and a poor prognosis (Kern et al, 1990;
Tateishi et al, 1991; Harpole et al, 1995a), especially when
combined with K-ras mutations (Kern et al, 1994) or Bcl-2 (Kim
et al, 1998), whereas others did not (Pfeiffer et al, 1996). Such
conflicting results can be explained by the low numbers of patients
included in the majority of the studies and by the use of different
methods to determine HER-2/neu status. Therefore, we performed
a systematic review of the literature to assess the prognostic value
of HER-2 overexpression on survival in patients with lung cancer.
MATERIALS AND METHODS
Publication selection
The eligibility criteria of the articles were as follows: to deal with
lung cancer only, to evaluate the association between c-erbB-2
status and survival, to measure c-erbB-2 expression in the tumour
and to be published as a full paper in the English or French
language literature. Abstracts were excluded from this research
because they provided insufficient data to evaluate the methodo-
logical quality of the trial and to perform meta-analysis.
The search was performed by consulting the Medline electronic
database, using the keywords ‘lung neoplasms’, ‘c-erbB2’, ‘erb2’,
‘erb-2’, ‘Her-2’, ‘Her2’, ‘Her2/neu’, ‘Her-2/neu’, ‘p185’, ‘epithelial
growth factor’ and ‘EGF’. Moreover, the bibliographies reported in
all the identified studies were used for completion of the trials
search. When authors reported, in several publications, the same
patient populations, only the most recent or complete study was
included in the analysis in order to avoid overlapping between
cohorts. The search ended on August 2002.
Methodological assessment
A team of nine investigators (including six physicians, one
pathologist, one biologist and one biostatistician) performed the
methodological evaluation of each trial using the European Lung
Cancer Working Party (ELCWP) scale. This scoring system was
previously described (Steels et al, 2001). Each item of the score was
quoted using an ordinal scale (possible values 2, 1, 0) by consensus
in meetings where at least two-thirds of the investigators needed to
be present. The participation of many readers was a guarantee for
the correct interpretation of the articles. The overall score assessed
several dimensions of methodology, grouped into four main
categories: the scientific design, the description of the laboratory
methods used to identify the presence of c-erbB-2, the generali-
sability of the results and the analysis of the study data. Each
category had a maximal score of 10 points with an overall maximal
theoretical score of 40 points. When an item was not applicable to
a study, its value was not taken into account in the total for the
category. The final scores were expressed as percentages, higher
values reflecting a better methodological quality. Studies included
in the systematic review were called ‘eligible’ and those providing
sufficient data for the meta-analysis ‘evaluable’.
Statistical method
A study was considered as significant if the P-value for the
statistical test comparing survival distributions between the groups
with and without c-erbB-2 expression was o0.05. The study was
called ‘positive’ when c-erbB-2 expression was identified as a
significant favourable prognostic factor for survival. The study was
called ‘negative’ if c-erbB-2 expression was associated with a
significant detrimental effect on survival. Finally, a study was
called ‘not significant’ if no difference between the groups
according to c-erbB-2 expression was detected. The association
between the quality scores or between a quality score and another
continuous variable was measured by the Spearman ranks
correlation coefficient. Nonparametric Mann–Whitney tests were
conducted to compare the distributions of the quality scores
according to the value of a dichotomic variable.
For the quantitative aggregation of survival results, we
compared the survival distributions between the two groups (with
or without c-erbB-2 overexpression) by the hazard ratio (HR)
according to a method that we have previously reported (Meert
et al, 2002a). For each trial, the HR was estimated by a method
depending on the data provided in the publications. The most
accurate method consisted of calculating the estimated HR and its
standard error from the reported results or to calculate them
directly using two of the following parameters: the confidence
interval (CI) for the HR, the logrank statistic, its P-value or the
O E statistic (difference between the numbers of observed and
expected events). If those data were not available, we looked at the
total number of events, the number of patients at risk in each
group and the logrank statistic or its P-value allowing calculation
of an approximation of the HR estimate. Finally, if the only
available data were in the form of graphical representations of the
survival distributions, we extracted from them survival rates at
some specified times in order to reconstruct the HR estimate and
its variance, with the assumption that the rate of patients censored
was constant during the study follow-up (Parmar et al, 1998). The
individual HR estimates were combined into an overall HR using
Peto’s method (Yusuf et al, 1985) that consisted of using a fixed-
effect model assuming homogeneity of the individual true HRs.
This assumption was tested by performing w
2 tests for hetero-
geneity. If the assumption of homogeneity had to be rejected,
we used a random-effects model. By convention, an observed
HR41 implied a worse survival for the group with c-erbB-2
expression. The impact of c-erbB-2 on survival was considered as
statistically significant if the 95% CI for the overall HR did not
overlap 1.
RESULTS
Studies selection and characteristics
A total of 39 studies, published between 1990 and 2002, were found
eligible (Kern et al, 1990, 1994; Tateishi et al, 1991, 1994; Volm
et al, 1992, 1993a; Harpole et al, 1995a,b, 1996; Giatromanolaki
et al, 1996a,b; Pfeiffer et al, 1996; Koukouraki et al, 1997, 2000;
MacKinnon et al, 1997; Pastorino et al, 1997; Visscher et al, 1997;
Yu et al, 1997; Graziano et al, 1998; Greatens et al, 1998; Hsieh
et al, 1998; Kim et al, 1998; Kwiatkowski et al, 1998; Nemunaitis
et al, 1998; Cantero et al, 1999, 2000; D’Amico et al, 1999;
Fu et al, 1999; Moldvay et al, 2000; Schneider et al, 2000;
Ardizzoni et al, 2001; Brabender et al, 2001; Liao et al, 2001; Shou
et al, 2001; Carbognani et al, 2002; Han et al, 2002; Hirsch et al,
2002; Potti et al, 2002; Selvaggi et al, 2002). Nine of the articles
were excluded because identical cohorts of patients were used
(studies that were excluded and included were, respectively,
references (Cantero et al, 1999) and (Cantero et al, 2000),
(Giatromanolaki et al, 1996b; Koukourakis et al, 1997, 2000) and
(Giatromanolaki et al, 1996a), (Harpole et al, 1995a,b) and
(Harpole et al, 1996), (Kern et al, 1994) and (Kern et al, 1990),
(Tateishi et al, 1991) and (Tateishi et al, 1994), (Volm et al, 1992)
and (Volm et al, 1993a,b).
The total number of patients included in the review was 4582
(range 31–483; median 117). The principal individual character-
istics of these different trials are reported in Table 1. Among them,
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adenocarcinoma only and one with small-cell carcinoma only.
Patients with locoregional disease (stages I–IIIB) were included in
19 studies, patients with advanced disease were included in two
studies, eight studies dealt with all stages diseases and, in one,
disease stages were not detailed. In all, 27 trials used immunohis-
tochemistry (IHC), two ELISA and one polymerase chain reaction
(PCR) to detect c-erbB-2 expression. Different antibodies were
used to assess c-erbB-2 expression by IHC. Assessment of c-erbB-2
status was carried out on surgical (24 studies) and/or bronchial
biopsies samples (four studies) whereas nodes obtained by
mediastinoscopy and sera were used, respectively, each in one
study.
Study results reports
According to c-erbB-2 expression, in NSCLC, 12 studies
(1583 patients) were ‘negative’, one was ‘positive’ (101 patients)
and 16 were ‘not significant’ (2705 patients) for survival.
In the study considering small-cell lung carcinoma (193
patients), c-erbB-2 overexpression tended to be of worse
prognosis.
Overall, according to the positivity threshold for c-erbB-2
expression as defined by the study authors, c-erbB-2 was expressed
in 31% of the NSCLC patients, in 30% of the patients with
adenocarcinoma and in 30% of the SCLC patients.
c-erbB-2 expression was found in 32% of the patients with
locoregional disease and in 36% of those with advanced disease.
Evaluability status for the meta-analysis was associated with trial
positivity: the rate of positive results was 57% for evaluable trials
(12 out of 21) compared to 11% for nonevaluable ones (one out of
nine) (P¼0.11).
Quality assessment
Before attempting to aggregate the results of the individual trials, a
qualitative assessment of each study was performed. The median
quality score for the pooled trials was 57.6% (range 37.4–82.6%).
The ‘design’ subscore had the lowest value except for the
nonevaluable studies where it was the ‘analysis results’ subscore
(Table 2). No statistically significant difference in terms of quality
score was observed between evaluable (range 40.5–82.6%) and
nonevaluable studies (range 37.4–68.1%) for meta-analysis
(median scores: 61.1 vs 54.3%, P¼0.09). The items not adequately
described (median score less than 1) were the statistical
considerations, the initial work-up of the disease and the number
of unassessable samples with description of exclusion causes. A
statistically significant difference in terms of methodological score
was found between the significant trials (range 47.3–82.6%) and
the nonsignificant trials (range 37.4–72.9%) (median overall
scores 61.2 vs 52.6%, P¼0.03), but not between the significant
and nonsignificant studies evaluable for the meta-analysis (61.2 vs
53.2%, P¼0.22). The difference in terms of quality score between
significant and nonsignificant studies is especially noted in the
‘results analysis’ subscore (including the follow-up description, the
survival analysis according to the HER-2, the univariate and the
multivariate analysis) with a better results description in the
significant studies (6.8 out of 10 vs 5.0 out of 10; P¼0.03). There
was no significant correlation between quality scores and the date
of publications of the studies or with the number of patients
included in these studies.
Table 1 Main characteristics and results of the eligible studies
Author Year Histology Stage N pts Sample Technique HR estimation Results
Ardizzoni (Ardizzoni et al, 2001) 2001 NSCLC III–IV 84 Serum ELISA (+IHC) Logrank+n events Negative
Brabender (Brabender et al, 2001) 2001 NSCLC I–IIIA 83 Surgery PCR Survival curves Negative
Cantero (Cantero et al, 2000) 2000 NSCLC I–IIIA 102 Surgery ELISA HR+CI Negative
Carbognani (Carbognani et al, 2002) 2002 NSCLC I–IIIA 78 Surgery IHC No data NS
D’Amico (D’Amico et al, 1999) 1999 NSCLC I 408 Surgery IHC Logrank+n events Negative
Fu (Fu et al, 1999) 1999 NSCLC I–IIIB 158 Surgery IHC No data NS
Giatromanolaki (Giatromanolaki et al, 1996a) 1996 NSCLC I–II 107 Surgery IHC Survival curves NS
Graziano (Graziano et al, 1998) 1998 NSCLC IIIA 47 Mediastinoscopy IHC No data NS
Greatens (Greatens et al, 1998) 1998 NSCLC I–IV 101 Surgery IHC No data Positive
Han (Han et al, 2002) 2002 NSCLC I 85 Surgery IHC Survival curves Negative
Harpole (Harpole et al, 1996) 1996 NSCLC I 275 Surgery IHC Logrank+n events Negative
Hirsch (Hirsch et al, 2002) 2002 NSCLC I–IIIA 187 Surgery+biopsies IHC (+ FISH) Survival curves NS
Hsieh (Hsieh et al, 1998) 1998 Adenoc I 42 Surgery IHC Logrank+n events Negative
Kern (Kern et al, 1990) 1990 NSCLC I–IV 44 Surgery+biopsies IHC HR+CI Negative
Kim (Kim et al, 1998) 1998 NSCLC I–IV 238 Surgery+biopsies IHC HR+CI NS
Kwiatkowski (Kwiatkowski et al, 1998) 1998 NSCLC I 243 Surgery IHC Logrank+n events NS
Liao (Liao et al, 2001) 2001 NSCLC I–IIIA 127 Surgery IHC Logrank+n events NS
MacKinnon (MacKinnon et al, 1997) 1997 Adenoc ? 162 Surgery IHC No data NS
Moldvay (Moldvay et al, 2000) 2000 NSCLC I–IV 227 Surgery IHC Logrank+n events NS
Nemunaitis (Nemunaitis et al, 1998) 1998 Adenoc I–IV 103 Surgery IHC No data NS
Pastorino (Pastorino et al, 1997) 1997 NSCLC I 483 Surgery IHC HR+CI NS
Pfeiffer (Pfeiffer et al, 1996) 1996 NSCLC I–IV 186 Surgery IHC Survival curves NS
Potti (Potti et al, 2002) 2002 SCLC Extensive 193 Biopsies IHC Survival curves Negative
Schneider (Schneider et al, 2000) 2000 NSCLC I–IIIA 103 Surgery IHC No data Negative
Selvaggi (Selvaggi et al, 2002) 2002 NSCLC I–III 130 Surgery IHC HR+CI Negative
Shou (Shou et al, 2001) 2001 NSCLC I–III 111 Surgery IHC Survival curves NS
Tateishi (Tateishi et al, 1994) 1994 Adenoc I–IV 119 Surgery IHC Survival curves Negative
Visscher (Visscher et al, 1997) 1997 Adenoc I–IV 31 Surgery IHC No data NS
Volm (Volm et al, 1993a) 1993 NSCLC I–III 241 Surgery IHC No data NS
Yu (Yu et al, 1997) 1997 NSCLC I–IIIA 116 Surgery IHC Survival curves Negative
NSCLC¼non-small-cell lung cancer; SCLC¼small-cell lung cancer; Adenoc¼adenocarcinoma; N pts¼number of patients; IHC¼immunohistochemistry; PCR¼polymerase
chain reaction; FISH¼fluorescent in situ hybridisation; NS¼not significant; ( )¼technique used to determine c-erbB-2 status but not used for correlation with survival.
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Out of the 14 significant studies, 12 are included in the meta-
analysis and nine out of the 16 nonsignificant studies are included
in the meta-analysis.
The HRs of the 21 evaluable studies were calculated by one of
the three methods reported in the Materials and Methods section.
Hazard ratios and 95% CIs were published in five trials. They were
approximated from the logrank statistic and the number of events
in seven studies. Finally, the HR and its variability had to be
extrapolated from the graphical representations of the survival
distributions in the nine others.
When considering only the 20 studies evaluating survival
in NSCLC, the test of heterogeneity was significant (P¼0.001).
Thus, we calculated the HR using a random-effects model
and obtained a value that was statistically significant: HR¼
1.55 (95% CI: 1.29–1.86) (Figure 1). When we compared
the studies with a quality score above and below the median
score (10 studies in each group), we found, respectively,
P-values of 0.006 and 0.009 for the tests of heterogeneity
and HR¼1.59 (95% CI: 1.23–2.04) and 1.50 (95% CI:
1.13–2.00).
When we only considered the 17 evaluable studies using
immunohistochemistry, there was still heterogeneity (Po0.001)
and the result of the meta-analysis was statistically significant: HR
was 1.46 (95% CI: 1.19–1.78), meaning that patients with a tumour
not expressing c-erbB-2 had a better survival rate.
DISCUSSION
In this systematic review, after aggregation of the available
survival results of lung cancer patients according to the
tumour expression of c-erbB-2, the presence of this receptor
appears to be a prognostic factor for a worse survival in
NSCLC.
Some potential important methodological biases need to be
discussed. In all, 57% of the evaluable trials were positive
compared to 11 % for the nonevaluable ones. There is thus, in
terms of publication, a potential bias in favour of the positive trials
(overestimation of the magnitude of the true effect of c-erbB-2
overexpression). Out of the 14 significant studies, 12 (86%) are
included in the meta-analysis, whereas only nine out of the 16
nonsignificant studies (56%) are included. This could suggest a
selection and evaluability bias. This systematic review identified a
statistically significant difference in the quality scores between
significant and nonsignificant studies evaluating the role of HER-
2/neu in lung cancer. The difference in quality score between
significant and nonsignificant studies is mainly due to a quality
difference in the report of analysis results that are better described
in the significant studies. The quality of the design, the description
of the laboratory method and the generalisability of the studies
were not different, meaning that the quality of the trials for these
variables were equivalent in the two groups. This is a known
phenomenon: studies with statistically significant results are more
likely to be published than those not showing such an effect. The
fact of nonpublishing of all nonsignificant data could bias the
meta-analysis results in favour of publications with significant
results. In order to know if the quality score difference between the













All (30) 5.00 6.42 6.66 5.62 57.58
Evaluable for MA (21) 5.00 6.42 6.66 6.25 61.07
Nonevaluable for MA (9) 5.00 6.42 7.50 3.75 54.34
P 0.15 0.94 0.83 0.02 0.09
Significant (14) 5.00 6.42 6.66 6.87 61.19
Nonsignificant (16) 4.50 6.07 6.66 5.00 52.64
P 0.30 0.26 0.27 0.03 0.03
Significant studies in MA (12) 5.00 6.42 6.66 7.50 61.19
Nonsignificant studies in MA (9) 5.00 6.42 6.66 6.25 53.18
P 0.91 0.47 0.59 0.14 0.22
MA¼meta-analysis. Scores are median scores of the studies.
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Kim et al (1998)
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Liao et al (2001)
Moldvay et al (2000) (adc)
Moldvay et al (2000) (sq)
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Pfeiffer et al (1996)
Selvaggi et al (2002)
Shou et al (2001)
Tateishi et al (1994)
Yu et al (1997)
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Figure 1 Results of the meta-analysis of all the studies. Ardizzoni et al
(2001); Brabender et al (2001); Cantero et al, (2000); D’Amico et al
(1999); Giatromanolaki et al (1996a,b); Han et al (2002); Harpole et al
(1996); Hirsch et al (2002); Hsieh et al (1998); Kern et al (1990) (adc); Kern
et al (1990) (sq); Kim et al (1998); Kwiatkowski et al (1998); Liao et al
(2001); Moldvay et al (2000) (adc); Moldvay et al (2000) (sq); Pastorino
et al (1997); Pfeiffer et al (1996); Selvaggi et al (2002); Shou et al (2001);
Tateishi et al (1994); Yu et al (1997); HR41 implies a worse survival for
the group with c-erbB2 expression. The square size is proportional to the
number of patients included in the study. The centre of the lozenge gives
the combined HR for the meta-analysis and its extremities give the 95% CI.
HER-2 and lung cancer
A-P Meert et al
962
British Journal of Cancer (2003) 89(6), 959–965 & 2003 Cancer Research UKsignificant and nonsignificant studies evaluable for the meta-
analysis could distort our results, we compared the studies
with a quality score above and below the median score. We
found the same results in the two groups: c-erbB-2 could be
a bad prognostic factor in NSCLC. The results of the aggrega-
tion have, of course, to be considered only exploratory, but could
help elaborate statistical considerations for an adequately
designed prospective study. If such a study confirmed that c-
erbB-2 is a bad prognostic factor for survival, the importance of
this prognostic biological factor will probably be small in
comparison with other factors such as stage, age or performance
status. Indeed, an HR of 1.5 does not mean a large effect of c-erbB-
2 on survival and does not constitute a useful factor at the
individual level. In our systematic review, out of the 30 articles,
eight publications found that c-erbB-2 was a factor of worse
prognosis in multivariate analysis.
The techniques used to detect c-erbB-2 expression might also be
potential sources of biases. Immunohistochemistry was most
frequently used. Immunohistochemical results can vary according
to the primary antibody used (Press et al, 1994). A number of
antibodies were reported in the literature. The dilution of the
antibody was sometimes different, leading to problems in
comparison among the studies because the sensitivity of the
method depends on the antibody concentration. Immunohisto-
chemistry depends on the tissue conservation (fixation in
comparison with frozen samples decreases the sensitivity of p185
detection by IHC (Marks et al, 1994)) and on the antigen retrieval
technique. Moreover, this technique remains mainly qualitative
due to some subjectivity in the assessment. The cutoff determining
the c-erbB-2 positivity is often arbitrary and varies according to
the investigators from a few percent to more than 30% of the
tumour cells. The use of different cutoff points is of critical
importance (Lee et al, 1995). The choice of a cutoff is often
arbitrary, although the selection of the median value of the
expression levels could be a standard approach to analyse new
prognostic factors, even if it may lead to some loss of information.
An optimal threshold needs to be defined for c-erbB-2. Lastly,
whether membrane or cytoplasmic reactivity should be considered
in lung cancer is not clear and the authors assessed c-erbB-2 in
different ways.
Therefore, molecular biology techniques are actually
necessary in order to validate immunohistochemistry results
as already performed in breast cancer. On the other hand,
the advantages of immunohistochemistry are the maintenance
of the tissue architecture, the ability to localise the antigen
and probably a most applicable and cost-effective technique
for routine use. c-erbB-2 overexpression can be associated with
cleavage of the extracellular domain and its accumulation in the
blood (Pupa et al, 1993). A good correlation between c-erbB-2
expression in tissue (detected by IHC) and in serum (detected
by enzyme immunoassay ELISA) was found in NSCLC (Diez
et al, 1997) and in adenocarcinoma (Osaki et al, 1995), but
a lack of correlation between this circulating oncoprotein
and tissue expression in NSCLC was found by others (Ardizzoni
et al, 2001). The inconvenience of ELISA is the requirement
of fresh or frozen tissue and calculation of an average c-erbB-2
content of tumour and normal tissue, but the availability for
measuring the circulating levels of this protein is an interesting
opportunity to assess its overexpression in patients with
tumours that are not easily accessible for biopsy. Finally, Hirsch
et al (2002) found a good correlation between the IHC and FISH
results in twothirds of the 51 tumours investigated. Demonstration
of HER-2/neu overexpression in NSCLC using a standardised
method is essential for establishing clinical trials for anti-HER-2
drugs.
Systematic reviews of the literature are different from meta-
analyses of individual patient data. The first approach is only
based on fully published studies and provides an exhaustive
and critical analysis of the topic with a methodology based
on the criteria of Mulrow (1987) and with data aggregation
when possible. The second approach is a new study taking
into account all performed trials on the topic, published or
not, requiring individual data update by the investigators.
Our review thus took into account only fully published
studies. We did not look for unpublished trials and abstracts
because our methodology requires data available in full
publications only. In addition, our review deals with prognostic
factors studies and, as they are more often retrospective, it is
much more difficult to identify unpublished data than for
prospective clinical trials data.
As already highlighted in our previous meta-analyses, other
potential biases such as language bias or problem in the method of
extrapolation of the HR must also be considered (Steels et al, 2001;
Meert et al, 2002a,b).
Why c-erbB-2 overexpression could confer a worse prognosis
in NSCLC is not known, especially as it is not related to disease
extension and histological subtype. There are some hypotheses
with respect to this. c-erbB-2 overexpression regulates cell
adhesion and invasive growth of cancer through its association
with the cadherin–catenin complex (Ochiai et al, 1994) and is
associated with increased migratory capacity (Bernstein et al,
1994). The coexpression of c-erbB-2 with the EGF-R seems
to be more frequent in patients with metastases and seems
to be associated with inferior survival (Tateishi et al, 1994).
Moreover, c-erbB-2 overexpression defined a subgroup of
node-negative patients with low angiogenesis and prognosis
similar to patients bearing high angiogenesis (Giatromanolaki
et al, 1996b), supporting the idea that c-erbB-2 expression
is a mechanism activated in NSCLC to enable cancer cell migration
in tumours with poor vasculature. The potential worse prognosis
of NSCLC that express c-erbB-2 is potentially important for
prognostic reasons and treatment purposes in addition to
improving our understanding of lung cancer biology. Identifica-
tion of prognostic factors allows defining high-risk groups of
patients for whom specific therapy might be necessary, or a
stratification has to be performed in controlled trials. Moreover,
c-erbB-2 might be a potential therapeutic target and its
expression may be linked to a chemoresistant phenotype in
NSCLC (Tsai et al, 1996). Actually, trastuzumab (Herceptin
R),
a humanised monoclonal antibody that recognises the
HER-2/Neu protein receptor, is under investigation for the
treatment of lung cancers overexpressing HER-2/Neu, but
the choice of the method of detection and the level of
Her-2/Neu expression required to obtain a potential therapeutic
effect from trastuzumab therapy have not yet been established in
lung cancer.
In conclusion, HER-2/neu expression in NSCLC could be a bad
prognostic factor in NSCLC, but assessment of c-erbB-2 expression
in lung cancer presents several difficulties: the immunohistochem-
ical techniques used to detect its expression and the criteria of
positivity varying among institutions. There is, in the literature, a
bias favouring the significant studies where the results are
described better. Our meta-analysis needs to be confirmed by an
adequately designed prospective study in an appropriate multi-
variate analysis setting taking into account the classical well-
defined prognostic factors for lung cancer.
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